Literature DB >> 18236780

The effect of beta-cyclodextrin complexation on the bioavailability and hepatotoxicity of clotrimazole.

C S Yong1, D X Li, B Prabagar, B C Park, S J Yi, B K Yoo, W S Lyoo, J S Woo, J D Rhee, J A Kim, H G Choi.   

Abstract

Clotrimazole, a poorly water-soluble antimycotic agent, is a promising therapeutic agent for various diseases including cancer and sickle cell anemia. The oral bioavailability and hepatic toxicity of clotrimazole were compared with its beta-cyclodextrin inclusion form which was prepared by the spray-drying method. The inclusion complex gave significantly higher initial plasma concentrations, Cmax and AUC than did clotrimazole alone, indicating that the drug from the inclusion compound could be more easily absorbed in rats. Furthermore, mice treated with the inclusion compound showed significantly higher GOT/GPT values compared to clotrimazole alone. The inclusion compound also induced hypertrophy of hepatic cells by fat accumulation and disappearance of hepatic sinusoids, indications of pathological changes of liver, suggesting that the inclusion compound could induce more severe tissue damage in the liver than clotrimazole alone. Thus, hepatotoxicity of clotrimazole seems to be correlated with the enhanced oral bioavailability by inclusion complexation. Our results suggest that, in the development of a novel oral product, appearance or enhancement of hepatic toxicity must be considered along with oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18236780

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  7 in total

1.  Clotrimazole as a Cancer Drug: A Short Review.

Authors:  S Kadavakollu; C Stailey; C S Kunapareddy; S White
Journal:  Med Chem (Los Angeles)       Date:  2014

2.  Electrophysiological Studies into the Safety of the Anti-diarrheal Drug Clotrimazole during Oral Rehydration Therapy.

Authors:  Willem S Lexmond; Paul A Rufo; Edda Fiebiger; Wayne I Lencer
Journal:  PLoS Negl Trop Dis       Date:  2015-09-25

3.  Nanomicellar Formulation of Clotrimazole Improves Its Antitumor Action toward Human Breast Cancer Cells.

Authors:  Mariah C Marcondes; Anne C S Fernandes; Ivaldo Itabaiana; Rodrigo O M A de Souza; Mauro Sola-Penna; Patricia Zancan
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

4.  Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.

Authors:  Tyree H Kiser; Douglas N Fish; Christina L Aquilante; Joseph E Rower; Michael F Wempe; Robert MacLaren; Isaac Teitelbaum
Journal:  Crit Care       Date:  2015-02-03       Impact factor: 9.097

Review 5.  VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis.

Authors:  Andrea Magrì; Simona Reina; Vito De Pinto
Journal:  Front Chem       Date:  2018-04-06       Impact factor: 5.221

6.  A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase.

Authors:  Aldo Segura-Cabrera; Reshmi Tripathi; Xiaoyi Zhang; Lin Gui; Tsui-Fen Chou; Kakajan Komurov
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

7.  Morphologies in Solvent-Annealed Clotrimazole Thin Films Explained by Hansen-Solubility Parameters.

Authors:  Heike M A Ehmann; Andreas Zimmer; Eva Roblegg; Oliver Werzer
Journal:  Cryst Growth Des       Date:  2014-02-10       Impact factor: 4.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.